Editorials Comment On Loss Of Avastin Approval For Breast Cancer
 

Editorials have responded to FDA's announcement that it will revoke approval of the drug Avastin to treat metastatic breast cancer because of studies suggesting it does not extend women's lives and carries significant risks. Summaries appear below...

More...